Foundation Medicine, Bristol Myers Squibb Expand CDx Partnership to Investigational Cancer Drug
The companies are working to establish FoundationOne CDx as a companion diagnostic for BMS's investigational tyrosine kinase inhibitor repotrectinib.
Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug
The companies will jointly develop and commercialize Guardant360 CDx and Guardant360 TissueNext for taletrectinib treatment in advanced and metastatic NSCLC.
Alercell to Distribute Amoy Diagnostic Ros1 Gene Fusion Detection Kit in US
The 14-fusion PCR assay for lung cancer subtyping is available for research-use only but will be more broadly distributed when the kits gain FDA clearance.
Japanese Regulator Approves Foundation Medicine CDx for Roche's Rozlytrek in Lung Cancer
The approval will allow clinicians to identify NSCLC patients with ROS1 fusion genes who could benefit from treatment with Rozlytrek.
Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines
An IASLC survey showed that molecular testing is not performed in line with expert guidelines, which means only a minority of lung cancer patients are benefitting from precision oncology.